Partner Headlines - AMRN

  1. FDA Approvals And Changes For The Week Ending February 14, 2 ...

    Benzinga
  2. Amarin Announces FDA DMEP Does Not Plan to Re-instate ANCHOR ...

    Benzinga
  3. Benzinga's Top #PreMarket Losers

    Benzinga
  4. Amarin Announces FDA Review Division Response on ANCHOR SPA Agreement ...

    Benzinga
  5. FDA Delays Decision on Amarin's Vascepa Drug

    Benzinga
  6. Amarin Receives FDA Notification That Action on ANCHOR sNDA Review ...

    Benzinga
  7. Amarin's Vascepa: Too Limited A Market Or FDA Blunder?

    Benzinga
  8. Amarin Announces Notification of Patent Allowances Related to ...

    Benzinga
  9. New Statin Rules: Which Drugmakers Had Ties?

    YCharts
  10. Is Amarin’s Fish Oil Blockbuster Dream Kaput?

    YCharts
  11. UPDATE: Citigroup Upgrades Amarin on Valuation

    Benzinga
  12. Benzinga's Top Upgrades

    Benzinga
  13. Aegis Capital Corp. Reiterates on Amarin Corporation plc After ...

    Benzinga
  14. Market Wrap For Thursday, October 17: S&P Record High On Debt ...

    Benzinga
  15. Mid-Day Market Update: SanDisk Surges On Upbeat Results; IBM ...

    Benzinga
  16. Mid-Morning Market Update: Markets Open Lower; Goldman Sachs ...

    Benzinga
  17. Stocks Hitting 52-Week Lows

    Benzinga
  18. UPDATE: Aegis Capital Downgrades Amarin Following Negative Panel ...

    Benzinga
  19. Benzinga's Top Pre-Market Losers

    Benzinga
  20. Amarin Announces Negative FDA Advisory Committee Outcome for ...

    Benzinga
  21. Amarin Halted Ahead of FDA Advisory Committee to Review sNDA ...

    Benzinga
  22. Aegis Says FDA's Outlook 'Not As Negative As People Think' on ...

    Benzinga
  23. Aegis Capital Reiterates Buy on Amarin Corporation Following ...

    Benzinga
  24. Jefferies Reiterates Buy on Amarin Corporation on Continued Positive ...

    Benzinga
  25. Goldman Sachs Reiterates Neutral on Amarin Ahead of Advisory ...

    Benzinga
  26. Amarin Shares Up 5% as FDA Says October 16th Advisory Committee ...

    Benzinga
  27. Enrollment in Amarin REDUCE-IT Cardiovascular Outcomes Study ...

    Benzinga
  28. Amarin Reports 30th Patent for Vascepa

    Benzinga
  29. Amarin Submits Supplemental NDA for Novasep as Fourth Vascepa ...

    Benzinga
  30. UPDATE: Citigroup Raises PT on Amarin Following Lighter 2Q13 ...

    Benzinga
  31. UPDATE: Jefferies Lowers PT on Amarin on Continued ANCHOR Partnership ...

    Benzinga
  32. Amarin Announces USPTO Allowance for Application 13/614,129 Related ...

    Benzinga
  33. Amarin Announces Patent Allowance Related to Vascepa and FDA ...

    Benzinga
  34. Weekly Guru Bargains Highlights: PANL, THRX, ZNGA, LORL, AMRN

    GuruFocus
  35. Benzinga's Top Pre-Market Gainers

    Benzinga
  36. Amarin Completes Dosing in a Fixed-Dose Combination Study With ...

    Benzinga
  37. Amarin Closes Dosing in Fixed-Dose Combination Study with Vascepa

    Benzinga
  38. FDA's Orange Book Doesn't Include Amarin's Vascepa NCE Status ...

    Benzinga
  39. Benzinga's Top Pre-Market Gainers

    Benzinga
  40. Amarin Receives Patent Allowance for Application 13/623,450 Related ...

    Benzinga
  41. Amarin Announces David Stack Appointed to Board of Directors

    Benzinga
  42. Amarin Spikes Lower

    Benzinga
  43. UDPATE: Aegis Capital Raises PT on Amarin to $35

    Benzinga
  44. Citigroup Reiterates Buy Rating, $20 PT on Amarin Corporation

    Benzinga
  45. Benzinga's Top Pre-Market Losers

    Benzinga
  46. UPDATE: Citigroup Initiates Amarin at Buy on Vascepa Overhang ...

    Benzinga
  47. Benzinga's Top Pre-Market Gainers

    Benzinga
  48. Amarin Awarded Patent 8,318,715 for Vascepa by USPTO

    Benzinga
  49. Amarin Announces USPTO has Published Notification of Notice of ...

    Benzinga
  50. A Peek Into The Market Before The Trading Starts

    Benzinga
  51. Amarin Announces US Patent 8,314,086 Award for Vascepa

    Benzinga
  52. Mid-Morning Market Update: Markets Rallying; J.C. Penney Misses ...

    Benzinga
  53. Amarin Awarded US Patent 8,298,554 Issuance for Vascepa

    Benzinga
  54. UPDATE: Wedbush Securities Downgrades Amarin Corporation to Neutral, ...

    Benzinga
  55. Benzinga's M&A Chatter for Tuesday September 11, 2012

    Benzinga
  56. Benzinga's M&A Chatter for Thursday September 6, 2012

    Benzinga
  57. Amarin Announces Notification of Patent Allowances for U.S. Applications ...

    Benzinga
  58. Amarin Announces Notification of Patent Allowance for Vascepa ...

    Benzinga
  59. Amarin Announces Additional Publication of MARINE Phase 3 Clinical ...

    Benzinga
  60. Health Care Sector Wrap

    FoxBusiness
  61. Benzinga's Top Pre-Market Gainers

    Benzinga
  62. Health Care Sector Wrap

    FoxBusiness
  63. Health Care Sector Wrap

    FoxBusiness
  64. Amarin Corporation (AMRN) Sees Spike in Option Activity with ...

    MarketIntelligenceCenter
  65. Amarin's

    IBD
  66. Facebook Inc. - Class A, Starbucks Among Stocks Down on High ...

    FoxBusiness
  67. Amarin Announces FDA Approval of Vascepa Capsules for the Reduction ...

    Benzinga
  68. Amarin and Horizon Pharma Higher Ahead of PDUFA Dates

    Benzinga
  69. Health Care Sector Wrap

    FoxBusiness
  70. Amarin Responds to Erroneous Website Posting

    Benzinga
  71. Biotechs With Upcoming PDUFA Dates

    Benzinga
  72. UPDATE: Aegis Capital Initiates Amarin Corporation with Buy, ...

    Benzinga
  73. New Annual Highs: AMRN, DIS, and NWS

    SchaeffersResearch
  74. Health Care Sector Wrap

    FoxBusiness
  75. Amarin (AMRN) Gains 10.5% As Company Appears Close to Winning ...

    MarketIntelligenceCenter
  76. Amarin Corporation plc, Loral Space & Communications Gapping ...

    FoxBusiness
  77. UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT ...

    Benzinga
  78. CF Industries Holdings, SBA Communications Corporation Included ...

    FoxBusiness
  79. AMR101 Phase 3 Study Data in Patients With Diabetes Mellitus ...

    Benzinga
  80. Amarin Corporation plc (AMRN) Sees Above Average Option Activity ...

    MarketIntelligenceCenter
  81. Earnings Scheduled For May 8

    Benzinga
  82. Amarin

    IBD
  83. Amarin (AMRN) Up 20% on Patent News, Analyst Commentary

    MarketIntelligenceCenter
  84. Amarin Up 7% After FDA Announces it Will Not Convene FDA Panel ...

    Benzinga
  85. AMRN said the FDA accepted a new drug for review, while OII updated ...

    SchaeffersResearch
  86. Benzinga's M&A Chatter for Tuesday December 6, 2011

    Benzinga
Trading Center